Navigation Links
74 Percent EBITDA Improvement at Zeltia Group in 2010
Date:2/24/2011

MADRID, Feb. 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totaled 153.5 million euro in 2010 (approximately 211.4 million USD*), 24.4 percent more than in 2009 (123.4 million euro, or approximately 169.9 million USD). This performance is primarily attributable to a 70 percent increase in Yondelis® sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro (approximately 109.3 million USD) in 2010 (51.1 million euro, or approximately 70.3 million USD in 2009), of which 72.1 million (approximately 99.3 million USD) correspond to Yondelis® (43.8 million euro, or approximately 60.3 million USD in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro, or approximately 100.8 million USD in 2010, compared with 71.1 million euro, or approximately 97.9 million USD in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (approximately -5.3 million USD) (-15.3 million euro or approximately -21.0 million USD in 2009).

Net income attributable to the parent company rose 71 percent with respect to 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialized in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genomica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

This note is also available on the Zeltia web site: www.zeltia.com.

* All original figures are in Euros; dollar figures are estimated using the exchange rate: 1.3773.


'/>"/>
SOURCE Zeltia
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. 34 percent of Galician secondary schools exceed maximum recommended radon levels
2. 34 percent of Galician secondary schools exceed maximum recommended radon levels
3. Codexis Grows Revenue 35 Percent in Third Quarter; Raises 2010 Outlook
4. ReVisions Fenretinide (RT-101) Reduced Incidence of Choroidal Neovascularization by More Than 50 Percent in Patients With Geographic Atrophy in a Phase 2b Trial
5. Tecnalia investigates ecological cement that cuts CO2 emissions by up to 100 percent
6. ClearTrial to Demonstrate How a Top 20 Sponsor Achieved -1 Percent Cost Variance Across Their $130M Clinical Portfolio at Major Industry Conference
7. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
8. ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line
9. Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 Diabetes
10. New Assay Detects 100 Percent of Stage I, II and III Colon Cancers in Pre-Clinical Trials
11. Nearly 70 Percent of Health Professionals Support Biotechnologys Use in Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/2/2016)... The Department of Transport Management (DOTM) ... million US Dollar project, for the , Supply ... Enrolment, and IT Infrastructure , to ... implementation of Identity Management Solutions. Numerous renowned international vendors participated ... was selected for the most compliant and innovative ...
(Date:6/2/2016)... 2016 Perimeter Surveillance & Detection ... Physical Infrastructure, Support & Other Service  The ... offers comprehensive analysis of the global Border Security ... revenues of $17.98 billion in 2016. Now: ... leader in software and hardware technologies for advanced video ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):